DNLI Denali Therapeutics Inc.

8-K Current Report

Filed: January 6, 2026

Health Care

Biological Products, (No Diagnostic Substances)SEC EDGAR

Denali Therapeutics Inc. (DNLI) 8-K current report filed with SEC EDGAR on January 6, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• Denali provided a 2026 program update and milestone timeline in a January 6 press release
• Company confirmed participation in 44th Annual J.P. Morgan Healthcare Conference, indicating engagement with investors

+1 more insights

Other Denali Therapeutics Inc. 8-K Filings

8-K Feb 26, 2026

Get deeper insights on Denali Therapeutics Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.